← All news

FDA tentatively approves first generic lenacapavir. Zolgensma tumour cases shake gene therapy

Scanning electron micrograph of green HIV-1 virions budding from a lymphocyte, illustrating the FDA approval of generic lenacapavir for HIV prevention

By Bahram Hassanpourfard, Epidemiologist

Weekly briefing · 2 to 8 November 2026

Public health and prevention

HIV prevention moved closer to reach in poorer countries as the FDA gave tentative approval to Dr. Reddy’s generic version of lenacapavir, the only twice-yearly injection to prevent HIV. This clears the way for supply at about $40 a year in 120 low- and middle-income countries, although the generic cannot yet be sold in the US.

On alcohol, new research on older men found that heavier drinking raises the risk of death and gave no convincing support to the idea that moderate drinking prolongs life. That evidence arrives as advocates draw international lessons on putting cancer warnings on alcohol labels, and as Global Burden of Disease data show alcohol causing a growing share of deaths in Nigeria. UKHSA published its latest surveillance of antimicrobial resistance in gonococcal infection in England and Wales, a dataset that underpins treatment guidance. Asthma + Lung UK warned that bonfire smoke, firework pollution and cold air could combine to trigger life-threatening attacks in people with lung conditions.

Healthcare providers

Emergency care set the tone ahead of winter. The Royal College of Emergency Medicine warned that Scotland’s A&E system is at risk of collapse, with departments struggling more than a year ago and thousands of patients waiting 12 hours every month. In England, NHS England rolled out a national paediatric early warning system for emergency departments, which the college welcomed, and GIRFT published early findings and priorities from its first 20 system visits on chronic pain services.

Workforce tension resurfaced in Northern Ireland, where 96 per cent of responding eligible Royal College of Midwives members said they were willing to take industrial action again over delays to their 3.3 per cent pay award. Beyond hospitals, an investigation found access to continuous glucose monitors, insulin pumps, hybrid closed loop systems and smart insulin pens inconsistent across England, and local medical committees set out their positions on tirzepatide and the QOF obesity indicators, a sign of how weight-loss drugs are reaching general practice contracts.

Research and trials

Gene therapy faced its hardest questions in some time. Novartis confirmed that nine children treated with its spinal muscular atrophy therapy Zolgensma have developed tumours, seven disclosed for the first time, and in two there was evidence that the viral delivery vector had integrated into patient DNA, a finding with implications for the wider field. The same week, Sarepta said it would not restart enrolment in the paused Phase 3 trial meant to confirm the benefit of its Duchenne gene therapy Elevidys in older boys. Against that backdrop, the FDA accepted uniQure’s application for accelerated approval of its Huntington’s disease gene therapy ifezuntirgene inilparvovec under priority review, with an action date of 1 May; the agreed confirmatory study would randomise about 200 patients 2:1 against standard of care, with Total Functional Capacity at 36 months as the primary endpoint.

Elsewhere, new trials supported elafibranor and seladelpar in primary biliary cholangitis, with most patients whose alkaline phosphatase was still mildly raised reaching normal levels, MetaVia reported liver fat and weight reductions with its GLP-1/glucagon agonist in phase 1 and plans a phase 2 trial in alcohol-associated liver disease, and a Science Advances paper described dual-acting compounds that use zanamivir to deliver an acidifying domain to the virus surface as potent influenza inhibitors.

Deals and markets

The week’s sharpest reversal came in muscular dystrophy, where sevasemten, acquired by Servier from Edgewise for $1.55 billion upfront, failed its primary and secondary endpoints in a pivotal Becker cohort only five months after the deal. Big pharma kept buying early science regardless. Boehringer Ingelheim signed a heavily backloaded oncology collaboration with China’s Sino Biopharmaceutical worth more than $7 billion, covering six preclinical antibody-drug conjugate and T-cell engager programmes, and AbbVie paid Nxera $100 million upfront, with up to $1.37 billion in milestones, for a phase 1 gut-targeting EP4 agonist for inflammatory bowel disease. AbbVie is also expanding its research site in Oxford.

Manufacturing and biosimilars consolidated: Lonza agreed to buy Merck KGaA’s US CDMO business, five sites and about 1,100 staff, adding capacity in cell and gene therapy, viral vectors and bioconjugates; Fresenius partnered with WuXi Biologics on up to 37 biosimilar candidates aimed at originator markets worth over €370 billion; and Samsung Bioepis chose Teva to sell its Remicade and Enbrel biosimilars in the US in a deal worth up to $420 million. Third-quarter results were firmer: Novo Nordisk nudged up guidance on the strength of its Wegovy pill, Pfizer beat estimates on Eliquis and 32 per cent growth from launched and acquired products, and Moderna’s $1.3 billion in revenue gave it its first profitable quarter in two years as it prioritises cancer vaccines.

Approvals and safety

Safety concerns in neuromuscular disease extended to the MHRA, which issued interim risk mitigation advice on givinostat after several international reports of deaths in Duchenne patients taking it. The FDA granted accelerated approval to Johnson & Johnson’s subcutaneous Rybrevant Faspro for recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy, and, on 30 October, to Inovio’s Voceryq, the first plasmid DNA-based immunotherapy, for recurrent respiratory papillomatosis, where it will compete with Precigen’s product at the same $460,000 list price amid open questions about its delivery device. Australia’s TGA approved oral semaglutide for weight loss in an Australian first, with GPs able to prescribe four strengths by the end of the year.

The MHRA also recalled batches of Aspire’s tropicamide eye drops labelled with the wrong expiry date, flagged dosing table errors in Sandoz’s co-amoxiclav suspension information, and issued guidance on using non-clinical data generated outside the OECD framework in UK trial applications, while Health Canada warned of bacterial contamination in unauthorised injectable peptides sold online.


Source: Life Sciences Hub, lifesciences.apotekanalytics.com